Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of D… Read more
Bristol-Myers Squibb Company (BMY) - Total Liabilities
Latest total liabilities as of December 2025: $-45.11 Billion USD
Based on the latest financial reports, Bristol-Myers Squibb Company (BMY) has total liabilities worth $-45.11 Billion USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bristol-Myers Squibb Company - Total Liabilities Trend (1987–2024)
This chart illustrates how Bristol-Myers Squibb Company's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bristol-Myers Squibb Company Competitors by Total Liabilities
The table below lists competitors of Bristol-Myers Squibb Company ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
State Bank of India
PINK:SBKFF
|
USA | $72.70 Trillion |
|
British American Tobacco p.l.c.
NYSE:BTI
|
USA | $61.15 Billion |
|
S&P Global Inc
NYSE:SPGI
|
USA | $25.05 Billion |
|
Accenture plc
NYSE:ACN
|
USA | $32.78 Billion |
|
Stryker Corporation
NYSE:SYK
|
USA | $25.42 Billion |
|
Danaher Corporation
NYSE:DHR
|
USA | $28.83 Billion |
|
Newmont Goldcorp Corp
NYSE:NEM
|
USA | $21.28 Billion |
|
Contemporary Amperex Technology Co Ltd Class A
SHE:300750
|
China | CN¥603.80 Billion |
Liability Composition Analysis (1987–2024)
This chart breaks down Bristol-Myers Squibb Company's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | -4.72 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -0.81 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | -4.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bristol-Myers Squibb Company's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bristol-Myers Squibb Company (1987–2024)
The table below shows the annual total liabilities of Bristol-Myers Squibb Company from 1987 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $76.22 Billion | +16.05% |
| 2023-12-31 | $65.67 Billion | -0.04% |
| 2022-12-31 | $65.70 Billion | -10.38% |
| 2021-12-31 | $73.31 Billion | -9.05% |
| 2020-12-31 | $80.60 Billion | +3.01% |
| 2019-12-31 | $78.25 Billion | +275.12% |
| 2018-12-31 | $20.86 Billion | -3.89% |
| 2017-12-31 | $21.70 Billion | +25.02% |
| 2016-12-31 | $17.36 Billion | +0.21% |
| 2015-12-31 | $17.32 Billion | -7.68% |
| 2014-12-31 | $18.77 Billion | -19.65% |
| 2013-12-31 | $23.36 Billion | +4.93% |
| 2012-12-31 | $22.26 Billion | +30.15% |
| 2011-12-31 | $17.10 Billion | +10.79% |
| 2010-12-31 | $15.44 Billion | -4.84% |
| 2009-12-31 | $16.22 Billion | -6.11% |
| 2008-12-31 | $17.28 Billion | +10.69% |
| 2007-12-31 | $15.61 Billion | +0.17% |
| 2006-12-31 | $15.58 Billion | -7.95% |
| 2005-12-31 | $16.93 Billion | -16.32% |
| 2004-12-31 | $20.23 Billion | +14.56% |
| 2003-12-31 | $17.66 Billion | +8.58% |
| 2002-12-31 | $16.27 Billion | -0.34% |
| 2001-12-31 | $16.32 Billion | +94.34% |
| 2000-12-31 | $8.40 Billion | -0.84% |
| 1999-12-31 | $8.47 Billion | -2.61% |
| 1998-12-31 | $8.70 Billion | +12.09% |
| 1997-12-31 | $7.76 Billion | -4.40% |
| 1996-12-31 | $8.12 Billion | +0.10% |
| 1995-12-31 | $8.11 Billion | +12.50% |
| 1994-12-31 | $7.21 Billion | +16.96% |
| 1993-12-31 | $6.16 Billion | +28.78% |
| 1992-12-31 | $4.78 Billion | +32.12% |
| 1991-12-31 | $3.62 Billion | -4.64% |
| 1990-12-31 | $3.80 Billion | +11.25% |
| 1989-12-31 | $3.41 Billion | +2.65% |
| 1988-12-31 | $3.33 Billion | +20.51% |
| 1987-12-31 | $2.76 Billion | -- |